[go: up one dir, main page]

Floss et al., 2009 - Google Patents

Influence of elastin‐like peptide fusions on the quantity and quality of a tobacco‐derived human immunodeficiency virus‐neutralizing antibody

Floss et al., 2009

Document ID
1363364873793007694
Author
Floss D
Sack M
Arcalis E
Stadlmann J
Quendler H
Rademacher T
Stoger E
Scheller J
Fischer R
Conrad U
Publication year
Publication venue
Plant biotechnology journal

External Links

Snippet

The use of vaginal microbicides containing human immunodeficiency virus (HIV)‐ neutralizing antibodies (nAbs) is a promising strategy to prevent HIV‐1 infection. Although antibodies are predominantly manufactured using mammalian cells, elastin‐like peptide …
Continue reading at onlinelibrary.wiley.com (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)

Similar Documents

Publication Publication Date Title
Floss et al. Influence of elastin‐like peptide fusions on the quantity and quality of a tobacco‐derived human immunodeficiency virus‐neutralizing antibody
Floss et al. Biochemical and functional characterization of anti‐HIV antibody–ELP fusion proteins from transgenic plants
Ramessar et al. Cost-effective production of a vaginal protein microbicide to prevent HIV transmission
US7253341B2 (en) Denaturant stable and/or protease resistant, chaperone-like oligomeric proteins, polynucleotides encoding same, their uses and methods of increasing a specific activity thereof
Yuki et al. Induction of toxin‐specific neutralizing immunity by molecularly uniform rice‐based oral cholera toxin B subunit vaccine without plant‐associated sugar modification
CA2440358C (en) Denaturant stable and/or protease resistant, chaperone-like oligomeric proteins, polynucleotides encoding same and their uses
Teh et al. Characterization of VRC 01, a potent and broadly neutralizing anti‐HIV m A b, produced in transiently and stably transformed tobacco
US20100240597A1 (en) Methods of delivery of molecules to cells using a ricin subunit and compositions relating to same
De Buck et al. Fusion of an F c chain to a VHH boosts the accumulation levels in A rabidopsis seeds
de Virgilio et al. The human immunodeficiency virus antigen Nef forms protein bodies in leaves of transgenic tobacco when fused to zeolin
Marusic et al. Expression, intracellular targeting and purification of HIV Nef variants in tobacco cells
Yang et al. Development of transgenic rice seed accumulating a major Japanese cedar pollen allergen (Cry j 1) structurally disrupted for oral immunotherapy
Hernández-Velázquez et al. Tobacco seeds as efficient production platform for a biologically active anti-HBsAg monoclonal antibody
JP2022518614A (en) Methods of Producing Binder-Toxin Fusion Proteins in Plant Cells or Whole Plants
Sabalza et al. Functional characterization of the recombinant HIV-neutralizing monoclonal antibody 2F5 produced in maize seeds
Joensuu et al. Expression and purification of an anti-Foot-and-mouth disease virus single chain variable antibody fragment in tobacco plants
Roy et al. Rabies glycoprotein fused with B subunit of cholera toxin expressed in tobacco plants folds into biologically active pentameric protein
US20050059053A1 (en) Complex formation for the stabilisation and purification of proteins of interest
US20060172298A1 (en) Denaturat stable and/or protease resistant, chaperone-like oligomeric proteins, polynucleotides encoding same, their uses and methods of increasing a specific activity thereof
EP3559239B1 (en) Oligomeric vaccines from plants by s-tag-s-protein fusions
Gong et al. Recombinant expression, purification, and biophysical characterization of the transmembrane and membrane proximal domains of HIV‐1 gp41
Kang et al. Comparison of CD20 binding affinities of rituximab produced in Nicotiana benthamiana leaves and Arabidopsis thaliana Callus
Mikschofsky et al. Cholera toxin B (CTB) is functional as an adjuvant for cytoplasmatic proteins if directed to the endoplasmatic reticulum (ER), but not to the cytoplasm of plants
Zagorskaya et al. Recombinant monoclonal antibodies synthesized in plant expression systems: problems and prospects
EP1529844B2 (en) Complex formation for the stabilisation and purification of proteins of interest